For these reasons, MTX is a suitable candidate for this study and therefore it was selected as a model drug to achieve TSPO ligand-MTX conjugates, potentially useful for the treatment of TSPO-rich cancers, including brain tumors overexpressing the TSPO. This evidence concerns the gene TSPO and cancer.